¼¼°èÀÇ ÀÓ»ó½ÃÇè Àåºñ ¹× º¸Á¶ ¼Ö·ç¼Ç ½ÃÀå
Clinical Trial Equipment and Ancillary Solutions
»óǰÄÚµå : 1785999
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÀÓ»ó½ÃÇè Àåºñ ¹× º¸Á¶ ¼Ö·ç¼Ç ½ÃÀåÀº 2030³â±îÁö 47¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 31¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÀÓ»ó½ÃÇè Àåºñ ¹× º¸Á¶ ¼Ö·ç¼Ç ½ÃÀåÀº 2024-2030³â¿¡ CAGR 7.0%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 47¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¼Ò½ÌÀº CAGR 8.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 21¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼­ÇöóÀÌ/¹°·ù ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 6.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8¾ï 4,800¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀÓ»ó½ÃÇè Àåºñ ¹× º¸Á¶ ¼Ö·ç¼Ç ½ÃÀåÀº 2024³â¿¡ 8¾ï 4,800¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀ» 11.1%·Î, 2030³â±îÁö 9¾ï 8,310¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.4%¿Í 6.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀÓ»ó½ÃÇè Àåºñ ¹× º¸Á¶ ¼Ö·ç¼Ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Àåºñ¿Í º¸Á¶ ¼Ö·ç¼ÇÀº ÀÓ»ó½ÃÇèÀ» ¾î¶»°Ô È¿À²È­ÇÒ ¼ö Àִ°¡?

ÀÓ»ó½ÃÇèÀÇ È¿À²¼º°ú ¼º°ø ¿©ºÎ´Â ÀÓ»ó½ÃÇè ÇÁ·ÎÅäÄÝÀÇ ¿øÈ°ÇÑ ¼öÇàÀ» Áö¿øÇÏ´Â °íǰÁú Àåºñ¿Í º¸Á¶ ¼Ö·ç¼ÇÀÇ À¯¹«¿¡ µû¶ó Å©°Ô Á¿ìµË´Ï´Ù. ¿µ»ó Áø´Ü ½Ã½ºÅÛ¿¡¼­ ÁÖÀÔ ÆßÇÁ¿¡ À̸£±â±îÁö ÀÓ»ó½ÃÇè Àåºñ´Â ȯÀÚ ¸ð´ÏÅ͸µ ¹× Ä¡·á °³ÀÔ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÇÑÆí, ½ÇÇè½Ç ŰƮ, ½Ã·á äÃë Àåºñ, ÄݵåüÀÎ ¹°·ù µîÀÇ º¸Á¶ ¿ëǰÀº ¿©·¯ ±â°ü¿¡¼­ ÀÓ»ó½ÃÇèÀ» ¿øÈ°ÇÏ°Ô ÁøÇàÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ºÐ»êÇü ÀÓ»ó½ÃÇè(DCT)À¸·ÎÀÇ ÀüȯÀÌ ÁøÇàµÊ¿¡ µû¶ó ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­, ¿ø°Ý ¸ð´ÏÅ͸µ ÀåÄ¡¿Í °°Àº ÈÞ´ë¿ë ȯÀÚ Á᫐ ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Å¬¶ó¿ìµå ±â¹Ý Àç°í °ü¸® ½Ã½ºÅÛÀ» Æ÷ÇÔÇÑ eClinical ¼Ö·ç¼ÇÀ» äÅÃÇÏ¿© ÀÓ»ó½ÃÇè ¹°Ç°ÀÇ Á¶´Þ ¹× À¯ÅëÀ» ÃÖÀûÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àü ¼¼°è ÀÓ»ó½ÃÇè ½Ã¼³ÀÇ ÀÓ»ó½ÃÇè Àåºñ Ç¥ÁØÈ­¸¦ ÅëÇØ ±ÔÁ¦ ¿ä°Ç Áؼö¸¦ °­È­ÇÏ°í µ¥ÀÌÅÍÀÇ ¹«°á¼º°ú Àϰü¼ºÀ» º¸ÀåÇÕ´Ï´Ù. Àӻ󿬱¸°¡ Á¡Á¡ ´õ º¹ÀâÇØÁü¿¡ µû¶ó ÷´Ü ÀÓ»ó½ÃÇè Àåºñ¿Í ±ä¹ÐÇÏ°Ô Á¶Á¤µÈ °ø±Þ¸Á ¹°·ùÀÇ Çʿ伺ÀÌ ±× ¾î´À ¶§º¸´Ù °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇè ÀåºñÀÇ »õ·Î¿î Çõ½ÅÀ̶õ?

ÀÓ»ó½ÃÇè ÀåºñÀÇ ¹ßÀüÀº µ¥ÀÌÅÍ Á¤È®µµ, ȯÀÚ ¾ÈÀü, ¾÷¹« È¿À²¼ºÀ» Çâ»ó½Ã۰í, ½ÃÇè ¼öÇà ¹æ¹ýÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­ ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ±â±âÀÇ µîÀåÀ¸·Î ȯÀÚÀÇ ¹ÙÀÌÅ»À» ½Ç½Ã°£À¸·Î ÃßÀûÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó ÀÓ»ó½ÃÇè ±â°üÀ» ÀÚÁÖ ¹æ¹®ÇÒ Çʿ䰡 ÁÙ¾îµé¾î ȯÀÚµéÀÇ ¼øÀÀµµ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. AI ±â¹Ý ¿µ»óó¸® ½Ã½ºÅÛÀº ÀÓ»ó Æò°¡¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, Á¾¾çÇÐ ¹× ½Å°æÇÐ ÀÓ»ó½ÃÇè¿¡¼­ °íÁ¤¹Ð ¹æ»ç¼±ÇÐÀû ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ÀÚµ¿È­µÈ ½Ã·á ó¸® ÀåºñÀÇ ÅëÇÕÀº ½ÇÇè½Ç ¿öÅ©Ç÷ο츦 °¡¼ÓÈ­ÇÏ°í ½Ã·á ºÐ¼®ÀÇ ÆíÂ÷¸¦ ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ¶ÇÇÑ ÀÓ»ó½ÃÇè¿¡ ½º¸¶Æ® ÁÖÀÔ ½Ã½ºÅÛ µµÀÔÀ¸·Î Á¤È®ÇÑ ¾à¹° Åõ¿©¸¦ º¸ÀåÇϰí ÀÓ»ó½ÃÇè ¾à¹° Åõ¿©ÀÇ ÀÎÀû ¿À·ù¸¦ °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù. ÀÓ»ó °ø±Þ¸Á °ü¸®¿¡¼­ ºí·ÏüÀÎ ±â¼úÀÇ È°¿ëÀÌ È®´ëµÊ¿¡ µû¶ó ÃßÀû¼ºÀÌ °­È­µÇ¾î À§Á¶ ÀÇ·á±â±â°¡ ¿¬±¸ »ýŰ迡 À¯ÀԵǴ °ÍÀ» ¹æÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. µðÁöÅÐ ÀüȯÀÌ ÀÓ»ó ¿¬±¸¿¡ Áö¼ÓÀûÀ¸·Î ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ´Â °¡¿îµ¥, Çõ½ÅÀûÀÎ ÀÓ»ó½ÃÇè Àåºñ´Â ÀǾàǰ °³¹ß ¹× ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» °¡¼ÓÈ­ÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇèÀÇ ¹°·ù ¹× °ø±Þ¸Á °ü¸®´Â ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

ÀÓ»ó½ÃÇè Àåºñ ¹× ¾×¼¼¼­¸® °ü¸®´Â ±â¼ú ¹ßÀü°ú ±ÔÁ¦ ¿ä°Ç¿¡ ÈûÀÔ¾î ´õ¿í ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ÄݵåüÀÎ ¹°·ù´Â ½Ç½Ã°£ ¿Âµµ ¸ð´ÏÅ͸µ ¼¾¼­¸¦ ÅëÇØ ¿Âµµ¿¡ ¹Î°¨ÇÑ »ý¹°Á¦Á¦, ¹é½Å, ÀÓ»ó½ÃÇè¿ë ÀǾàǰÀÇ ¹«°á¼ºÀ» º¸ÀåÇÏ´Â µî Å« Çõ½ÅÀ» ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ¼ö¿ä ¿¹ÃøÀ» ÅëÇØ ÀÓ»ó½ÃÇè¿ë ÀǾàǰ °ø±Þ¸Á ¹°·ù¸¦ ÃÖÀûÈ­Çϰí, ³¶ºñ¸¦ ÁÙÀ̸ç, ÀÓ»ó½ÃÇè ±â°ü¿¡ Áß¿äÇÑ Àåºñ¸¦ Àû½Ã¿¡ ¹è¼ÛÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. ȯÀÚ Á÷Á¢ °ø±Þ(DTP) ¸ðµ¨¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ºÐ»êÇü ÀÓ»ó½ÃÇè¿¡¼­ ¾à¹°Àü´ÞÀ» °£¼ÒÈ­Çϰí ȯÀÚ À¯Áö ¹× ¼øÀÀµµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ Æ®À© ±â¼úÀº ÀÓ»ó½ÃÇè °ø±Þ¸Á ½Ã³ª¸®¿À ½Ã¹Ä·¹À̼ǿ¡ Àû¿ëµÇ¾î ½ºÆù¼­°¡ º´¸ñÇö»óÀ» ¿¹ÃøÇϰí ÀÚ¿ø ¹èºÐÀ» ÃÖÀûÈ­ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. RFID(¹«¼± ÀÚµ¿ ½Äº°)¿Í IoT(»ç¹°ÀÎÅͳÝ)¸¦ ÀÌ¿ëÇÑ ±â±â ÃßÀûÀº ÀÓ»ó½ÃÇè ¹°·ùÀÇ °¡½Ã¼º°ú È¿À²¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. °ø±Þ¸Á °ü¸®¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã°¡ °­È­µÊ¿¡ µû¶ó ÀÓ»ó½ÃÇè ÀÇ·ÚÀÚµéÀº À§ÇèÀ» ÁÙÀÌ°í µ¥ÀÌÅÍÀÇ ¹«°á¼ºÀ» À¯ÁöÇϱâ À§ÇØ ÄÄÇöóÀ̾𽺠Áß½ÉÀÇ ¹°·ù ¼Ö·ç¼ÇÀ» ¿ì¼±½ÃÇϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇè Àåºñ ¹× º¸Á¶ ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼ºÀå µ¿·ÂÀº ¹«¾ùÀΰ¡?

ÀÓ»ó½ÃÇè Àåºñ ¹× º¸Á¶ ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»ó½ÃÇèÀÇ º¹À⼺ Áõ°¡, ½ÃÇè ÀåºñÀÇ ±â¼ú ¹ßÀü, ºÐ»êÇü ¹× ÇÏÀ̺긮µå ½ÃÇè ¸ðµ¨·ÎÀÇ Àüȯ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ½Ç½Ã°£ ȯÀÚ ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­ ¹× ¿ø°Ý Áø´Ü ÀåÄ¡ÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. »ý¹°Á¦Á¦ ¹× ¼¼Æ÷-À¯ÀüÀÚ Ä¡·áÁ¦(CGT)ÀÇ º¸±ÞÀ¸·Î Ư¼ö ÄݵåüÀÎ ¹°·ù ¹× ÃÊÀú¿Â º¸°ü ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÓ»ó½ÃÇè ¼­ºñ½º¸¦ CRO(ÀÓ»ó½ÃÇè¼öʱâ°ü)¿¡ ¾Æ¿ô¼Ò½ÌÇÏ´Â Ãß¼¼°¡ Áõ°¡Çϸ鼭 ÷´Ü ÀÓ»ó½ÃÇè Àåºñ ¹× º¸Á¶ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó ¿¬±¸¿¡¼­ µðÁöÅÐ Àüȯ¿¡ ´ëÇÑ Á߿伺ÀÌ ³ô¾ÆÁö¸é¼­ AI ±â¹Ý ¿µ»ó ±â¼ú, ÀÚµ¿È­µÈ ½ÇÇè½Ç Àåºñ, ºí·ÏüÀÎÀ» Ȱ¿ëÇÑ °ø±Þ¸Á °ü¸® ½Ã½ºÅÛÀÇ µµÀÔÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦±â°üÀº ÀÓ»ó½ÃÇè Àåºñ ¹× ¹°·ù¿¡ ´ëÇØ º¸´Ù ¾ö°ÝÇÑ ±ÔÁ¤ Áؼö ±âÁØÀ» ¿ä±¸Çϰí ÀÖÀ¸¸ç, ½ºÆù¼­µéÀÌ °íǰÁúÀÇ °ËÁõµÈ ¼Ö·ç¼Ç¿¡ ÅõÀÚÇÒ °ÍÀ» Ã˱¸Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè ¼³°è°¡ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, Çõ½ÅÀûÀ̰í È¿À²ÀûÀÎ ±â¼ú ±â¹Ý Àåºñ ¹× °ü·Ã ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â ¾ÕÀ¸·Îµµ ½ÃÀå È®´ëÀÇ ÁÖ¿ä µ¿·ÂÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(¼Ò½Ì, ¼­ÇöóÀÌ/¹°·ù, ¼­ºñ½º, ±âŸ À¯Çü), ´Ü°è À¯Çü(´Ü°è I, ´Ü°è II, ´Ü°è III, ´Ü°è IV)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇÕ´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Clinical Trial Equipment and Ancillary Solutions Market to Reach US$4.7 Billion by 2030

The global market for Clinical Trial Equipment and Ancillary Solutions estimated at US$3.1 Billion in the year 2024, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Sourcing, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Supply / Logistics segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$848.0 Million While China is Forecast to Grow at 11.1% CAGR

The Clinical Trial Equipment and Ancillary Solutions market in the U.S. is estimated at US$848.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$983.1 Million by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Clinical Trial Equipment and Ancillary Solutions Market - Key Trends & Drivers Summarized

How Are Equipment and Ancillary Solutions Streamlining Clinical Trials?

The efficiency and success of clinical trials depend heavily on the availability of high-quality equipment and ancillary solutions that support the smooth execution of study protocols. Clinical trial equipment, ranging from diagnostic imaging systems to infusion pumps, plays a critical role in patient monitoring and therapeutic interventions. Meanwhile, ancillary supplies, including lab kits, sample collection devices, and cold chain logistics, ensure the seamless conduct of trials across multiple sites. The growing shift toward decentralized clinical trials (DCTs) has increased the demand for portable and patient-centric equipment, such as wearable biosensors and remote monitoring devices. Additionally, the adoption of eClinical solutions, including cloud-based inventory management systems, is optimizing the procurement and distribution of trial supplies. Standardization of trial equipment across global study sites is also enhancing compliance with regulatory requirements, ensuring data integrity and consistency. As clinical research becomes increasingly complex, the need for sophisticated trial equipment and well-coordinated supply chain logistics is more pronounced than ever.

What Are the Emerging Innovations in Clinical Trial Equipment?

Advancements in clinical trial equipment are reshaping the way studies are conducted, enhancing data accuracy, patient safety, and operational efficiency. The rise of wearable biosensors and remote monitoring devices is enabling real-time tracking of patient vitals, reducing the need for frequent site visits and improving patient compliance. AI-powered imaging systems are revolutionizing clinical endpoints assessment, offering high-precision radiological analysis for oncology and neurology trials. The integration of automated sample processing equipment is accelerating laboratory workflows, minimizing variability in specimen analysis. Additionally, the deployment of smart infusion systems in clinical trials is ensuring accurate drug dosing, reducing human errors in investigational drug administration. The increasing use of blockchain technology in clinical supply chain management is enhancing traceability, preventing counterfeit medical devices from entering the research ecosystem. As digital transformation continues to influence clinical research, innovative trial equipment is becoming an essential component in accelerating drug development and regulatory approvals.

How Is Logistics and Supply Chain Management Evolving in Clinical Trials?

The management of clinical trial equipment and ancillary supplies is becoming more sophisticated, driven by technological advancements and regulatory requirements. Cold chain logistics is witnessing significant innovation, with real-time temperature monitoring sensors ensuring the integrity of temperature-sensitive biologics, vaccines, and investigational drugs. AI-driven demand forecasting is optimizing trial supply chain logistics, reducing wastage and ensuring timely delivery of critical equipment to trial sites. The increasing reliance on direct-to-patient (DTP) supply models is streamlining drug delivery in decentralized clinical trials, improving patient retention and adherence. Additionally, digital twin technology is being employed to simulate trial supply chain scenarios, allowing sponsors to predict bottlenecks and optimize resource allocation. The use of RFID (Radio Frequency Identification) and IoT (Internet of Things) in equipment tracking is enhancing visibility and efficiency in clinical trial logistics. As regulatory scrutiny over supply chain management intensifies, clinical trial sponsors are prioritizing compliance-driven logistics solutions to mitigate risks and maintain data integrity.

What’s Driving the Growth of the Clinical Trial Equipment and Ancillary Solutions Market?

The growth in the clinical trial equipment and ancillary solutions market is driven by several factors, including the increasing complexity of clinical trials, technological advancements in trial equipment, and the shift toward decentralized and hybrid trial models. The rising demand for real-time patient monitoring solutions is fueling the adoption of wearable biosensors and remote diagnostic devices. The proliferation of biologics and cell and gene therapies (CGTs) is intensifying the need for specialized cold chain logistics and ultra-low temperature storage solutions. Additionally, the growing trend of outsourcing clinical trial services to contract research organizations (CROs) is driving investments in advanced trial equipment and ancillary solutions. The increasing emphasis on digital transformation in clinical research is propelling the adoption of AI-driven imaging technologies, automated laboratory equipment, and blockchain-powered supply chain management systems. Furthermore, regulatory agencies are mandating stricter compliance standards for trial equipment and logistics, encouraging sponsors to invest in high-quality, validated solutions. As clinical trial designs continue to evolve, the demand for innovative, efficient, and technology-driven equipment and ancillary solutions will remain a key driver of market expansion.

SCOPE OF STUDY:

The report analyzes the Clinical Trial Equipment and Ancillary Solutions market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Sourcing, Supply/Logistics, Service, Other Types); Phase Type (Phase I, Phase II, Phase III, Phase IV)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â